Login / Register
Menu
About us
Products
Primary antibodies
Gallery
Distributors
Validation
Tissue Microarrays
Publications
Large Scale Studies
Further Publications
Events
Quiz
Contact
About us
Products
Primary antibodies
Gallery
Distributors
Validation
Tissue Microarrays
Publications
Large Scale Studies
Further Publications
Events
Quiz
Contact
Search
×
Cancer Tissue Gallery INSM1
Path
Created with Sketch.
Go to INSM1 Normal Tissue Gallery
Go back to Product Page
Adrenal gland - INSM1 negative adrenocortical adenoma.
Adrenal gland – INSM1 negative adrenocortical adenoma.
Adrenal gland - INSM1 negative adrenocortical carcinoma.
Adrenal gland – INSM1 negative adrenocortical carcinoma.
Adrenal gland - Pheochromocytoma showing moderate to strong INSM1 immunostaining in tumor cells.
Adrenal gland – Pheochromocytoma showing moderate to strong INSM1 immunostaining in tumor cells.
Colon - Colorectal adenocarcinoma showing moderate to strong INSM1 immunostaining in a fraction of cells (30-50%).
Colon – Colorectal adenocarcinoma showing moderate to strong INSM1 immunostaining in a fraction of cells (30-50%).
Esophagus - INSM1 negative adenocarcinoma.
Esophagus – INSM1 negative adenocarcinoma.
Esophagus - Squamous cell carcinoma showing weak INSM1 immunostaining in a small fraction of cells (<5%).
Esophagus – Squamous cell carcinoma showing weak INSM1 immunostaining in a small fraction of cells (<5%).
Ileum - Neuroendocrine tumor showing moderate INSM1 immunostaining in tumor cells.
Ileum – Neuroendocrine tumor showing moderate INSM1 immunostaining in tumor cells.
Kidney - INSM1 negative clear cell renal cell carcinoma.
Kidney – INSM1 negative clear cell renal cell carcinoma.
Kidney - INSM1 negative papillary renal cell carcinoma.
Kidney – INSM1 negative papillary renal cell carcinoma.
Larynx - INSM1 negative squamous cell carcinoma.
Larynx – INSM1 negative squamous cell carcinoma.
Liver - INSM1 negative cholangiocellular carcinoma.
Liver – INSM1 negative cholangiocellular carcinoma.
Liver - INSM1 negative hepatocellular carcinoma.
Liver – INSM1 negative hepatocellular carcinoma.
Lung - INSM1 negative adenocarcinoma.
Lung – INSM1 negative adenocarcinoma.
Lung - Neuroendocrine tumor with strong INSM1 positivity of tumor cells.
Lung – Neuroendocrine tumor with strong INSM1 positivity of tumor cells.
Lung - Small cell neuroendocrine carcinoma showing strong INSM1 immunostaining in most tumor cells.
Lung – Small cell neuroendocrine carcinoma showing strong INSM1 immunostaining in most tumor cells.
Lymph node - Diffuse large B-cell lymphoma showing a weak to moderate INSM1 immunostaining in a fraction of cells (>50%).
Lymph node – Diffuse large B-cell lymphoma showing a weak to moderate INSM1 immunostaining in a fraction of cells (>50%).
Ovary - Endomeroid carcinoma showing a weak to moderate INSM1 immunostaining in tumor cells.
Ovary – Endomeroid carcinoma showing a weak to moderate INSM1 immunostaining in tumor cells.
Pancreas - INSM1 negative acinar cell carcinoma.
Pancreas – INSM1 negative acinar cell carcinoma.
Pancreas - Neuroendocrine tumor showing strong INSM1 immunostaining in tumor cells.
Pancreas – Neuroendocrine tumor showing strong INSM1 immunostaining in tumor cells.
Pharynx - Squamous cell carcinoma showing moderate INSM1 immunostaining in a fraction of tumor cells (20-30%).
Pharynx – Squamous cell carcinoma showing moderate INSM1 immunostaining in a fraction of tumor cells (20-30%).
Pharynx - Squamous cell carcinoma showing moderate to strong INSM1 immunostaining in a fraction of tumor cells (30-50%).
Pharynx – Squamous cell carcinoma showing moderate to strong INSM1 immunostaining in a fraction of tumor cells (30-50%).
Prostate - INSM1 negative adenocarcinoma (Gleason 3+3=6).
Prostate – INSM1 negative adenocarcinoma (Gleason 3+3=6).
Prostate - Small cell neuroendocrine carcinoma exhibiting strong INSM1 immunostaining in tumor cells.
Prostate – Small cell neuroendocrine carcinoma exhibiting strong INSM1 immunostaining in tumor cells.
Salivary gland - INSM1 negative pleomorphic adenoma.
Salivary gland – INSM1 negative pleomorphic adenoma.
Skin - INSM1 negative malignant melanoma.
Skin – INSM1 negative malignant melanoma.
Skin - Merkel cell carcinoma with strong INSM1 positivity of tumor cells.
Skin – Merkel cell carcinoma with strong INSM1 positivity of tumor cells.
Stomach - INSM1 negative gastric adenocarcinoma.
Stomach – INSM1 negative gastric adenocarcinoma.
Stomach - INSM1 negative gastrointestinal stromal tumor (GIST).
Stomach – INSM1 negative gastrointestinal stromal tumor (GIST).
Testis - INSM1 negative seminoma.
Testis – INSM1 negative seminoma.
Thymus - INSM1 negative thymoma containing some residual INSM1 positive thymic epithelial cells.
Thymus – INSM1 negative thymoma containing some residual INSM1 positive thymic epithelial cells.
Thyroid - INSM1 negative papillary carcinoma.
Thyroid – INSM1 negative papillary carcinoma.
Thyroid - Medullary carcinoma showing moderate to strong INSM1 immunostaining. Adjacent normal thyroid follicles are INSM1 negative.
Thyroid – Medullary carcinoma showing moderate to strong INSM1 immunostaining. Adjacent normal thyroid follicles are INSM1 negative.
Urinary bladder - INSM1 negative muscle-invasive urothelial carcinoma.
Urinary bladder – INSM1 negative muscle-invasive urothelial carcinoma.
Urinary bladder - Small cell neuroendocrine carcinoma exhibiting strong INSM1 positivity in tumor cells.
Urinary bladder – Small cell neuroendocrine carcinoma exhibiting strong INSM1 positivity in tumor cells.
Uterus - INSM1 negative endometroid carcinoma of the endometrium.
Uterus – INSM1 negative endometroid carcinoma of the endometrium.